{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:16Z","timestamp":1786980916146,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:00:00Z","timestamp":1593820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001829","name":"Utrecht University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001829","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Ibrutinib is a first-in-class Bruton\u2019s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial concentrations in human subjects, especially when CYP3A4 is inhibited. Ibrutinib has unexplained nephrotoxicity and high metabolite concentrations are also found in kidneys of Cyp3a knockout mice. Here, a mechanism is proposed where the intermediate cysteine metabolite is bioactivated. The metabolism of ibrutinib through this glutathione cycle was confirmed in cultured human renal proximal tubule cells. Ibrutinib-mediated toxicity was enhanced in-vitro by inhibitors of breast cancer resistance protein (BCRP), P-glycoprotein (P-gp) and multidrug resistance protein (MRP). This was a result of accumulating cysteine metabolite levels due to efflux inhibition. Finally, through inhibition of downstream metabolism, it was shown now that direct conjugation was responsible for cysteine metabolite toxicity.<\/jats:p>","DOI":"10.1007\/s10637-020-00970-x","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T18:02:37Z","timestamp":1593885757000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Extrahepatic metabolism of ibrutinib"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7935-640X","authenticated-orcid":false,"given":"Johannes J. M.","family":"Rood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-4159","authenticated-orcid":false,"given":"Amer","family":"Jamalpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-5814","authenticated-orcid":false,"given":"Stephanie","family":"van Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0251-071X","authenticated-orcid":false,"given":"Matthijs J.","family":"van Haren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8150","authenticated-orcid":false,"given":"Roeland E.","family":"Wasmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-8096","authenticated-orcid":false,"given":"Manoe J.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-8602","authenticated-orcid":false,"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-1074","authenticated-orcid":false,"given":"Rosalinde","family":"Masereeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0118-561X","authenticated-orcid":false,"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-7937","authenticated-orcid":false,"given":"Rolf W.","family":"Sparidans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"key":"970_CR1","doi-asserted-by":"publisher","unstructured":"Molica S, Matutes E, Tam C, Polliack A (2019) Ibrutinib in the treatment of chronic lymphocytic leukemia: 5\u2009years on. Hematol Oncol Hon.2695. https:\/\/doi.org\/10.1002\/hon.2695","DOI":"10.1002\/hon.2695"},{"key":"970_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394. https:\/\/doi.org\/10.1200\/JCO.2012.42.7906","journal-title":"J Clin Oncol"},{"key":"970_CR3","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1080\/10428194.2017.1369074","volume":"59","author":"LS Hiemcke-Jiwa","year":"2017","unstructured":"Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH et al (2017) Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Leuk Lymphoma 59:1256\u20131259. https:\/\/doi.org\/10.1080\/10428194.2017.1369074","journal-title":"Leuk Lymphoma"},{"key":"970_CR4","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie TA (2016) Targeted covalent inhibitors for drug design. Angew Chem Int Ed 55:13408\u201313421. https:\/\/doi.org\/10.1002\/anie.201601091","journal-title":"Angew Chem Int Ed"},{"key":"970_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","volume":"20","author":"Q Liu","year":"2013","unstructured":"Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 20:146\u2013159. https:\/\/doi.org\/10.1016\/j.chembiol.2012.12.006","journal-title":"Chem Biol"},{"key":"970_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.114.060061","volume":"43","author":"E Scheers","year":"2015","unstructured":"Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G (2015) Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43:289\u2013297. https:\/\/doi.org\/10.1124\/dmd.114.060061","journal-title":"Drug Metab Dispos"},{"key":"970_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1110\/ps.8.3.689","volume":"8","author":"PJ Jakobsson","year":"1999","unstructured":"Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B (1999) Common structural features of MAPEG -- a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci 8:689\u2013692. https:\/\/doi.org\/10.1110\/ps.8.3.689","journal-title":"Protein Sci"},{"key":"970_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0076-6879(05)01028-1","volume":"401","author":"H Zhang","year":"2005","unstructured":"Zhang H, Jay Forman H, Choi J (2005) \u03b3-Glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol 401:468\u2013483. https:\/\/doi.org\/10.1016\/S0076-6879(05)01028-1","journal-title":"Methods Enzymol"},{"key":"970_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/dmd.114.061424","volume":"43","author":"Y Shibata","year":"2015","unstructured":"Shibata Y, Chiba M (2015) The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib. Drug Metab Dispos 43:375\u2013384. https:\/\/doi.org\/10.1124\/dmd.114.061424","journal-title":"Drug Metab Dispos"},{"key":"970_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.115.069203","volume":"44","author":"PA Dickinson","year":"2016","unstructured":"Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P (2016) Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 44:1201\u20131212. https:\/\/doi.org\/10.1124\/dmd.115.069203","journal-title":"Drug Metab Dispos"},{"key":"970_CR11","doi-asserted-by":"publisher","first-page":"E223","DOI":"10.1002\/ajh.25546","volume":"94","author":"S Manohar","year":"2019","unstructured":"Manohar S, Bansal A, Wanchoo R, Sakhiya V, Lucia S, Jhaveri KD (2019) Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol 94:E223\u2013E225. https:\/\/doi.org\/10.1002\/ajh.25546","journal-title":"Am J Hematol"},{"key":"970_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"key":"970_CR13","doi-asserted-by":"publisher","unstructured":"Brener ZZ, Brener H, Losev A (2020) Bruton\u2019s tyrosine kinase inhibitors and the kidney: focus on ibrutinib. J Oncol Pharm Pract 107815522090440. https:\/\/doi.org\/10.1177\/1078155220904406","DOI":"10.1177\/1078155220904406"},{"key":"970_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00441-009-0882-y","volume":"339","author":"MJ Wilmer","year":"2010","unstructured":"Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, Mathieson PW, Monnens LA, van den Heuvel LP, Levtchenko EN (2010) Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 339:449\u2013457. https:\/\/doi.org\/10.1007\/s00441-009-0882-y","journal-title":"Cell Tissue Res"},{"key":"970_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1021\/acs.molpharmaceut.5b00821","volume":"13","author":"P Caetano-Pinto","year":"2016","unstructured":"Caetano-Pinto P, Janssen MJ, Gijzen L, Verscheijden L, Wilmer MJG, Masereeuw R (2016) Fluorescence-based transport assays revisited in a human renal proximal tubule cell line. Mol Pharm 13:933\u2013944. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00821","journal-title":"Mol Pharm"},{"key":"970_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drup.2017.01.002","volume":"30","author":"P Caetano-Pinto","year":"2017","unstructured":"Caetano-Pinto P, Jansen J, Assaraf YG, Masereeuw R (2017) The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resist Updat 30:15\u201327","journal-title":"Drug Resist Updat"},{"key":"970_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0041-008X(90)90319-P","volume":"103","author":"JC Chen","year":"1990","unstructured":"Chen JC, Stevens JL, Trifillis AL, Jones TW (1990) Renal cysteine conjugate beta-lyase-mediated toxicity studied with primary cultures of human proximal tubular cells. Toxicol Appl Pharmacol 103:463\u2013473","journal-title":"Toxicol Appl Pharmacol"},{"key":"970_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00726-005-0243-4","volume":"30","author":"AJL Cooper","year":"2006","unstructured":"Cooper AJL, Pinto JT (2006) Cysteine S-conjugate \u03b2-lyases. Amino Acids 30:1\u201315","journal-title":"Amino Acids"},{"key":"970_CR19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1124\/jpet.103.052225.Chemotherapeutic","volume":"306","author":"L Zhang","year":"2003","unstructured":"Zhang L, Hanigan MH, Duescher RJ et al (2003) Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988\u2013994. https:\/\/doi.org\/10.1124\/jpet.103.052225.Chemotherapeutic","journal-title":"J Pharmacol Exp Ther"},{"key":"970_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbadis.2012.09.006","volume":"1832","author":"HAM Mutsaers","year":"2013","unstructured":"Mutsaers HAM, Wilmer MJG, Reijnders D, Jansen J, van den Broek PHH, Forkink M, Schepers E, Glorieux G, Vanholder R, van den Heuvel LP, Hoenderop JG, Masereeuw R (2013) Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta Mol basis Dis 1832:142\u2013150. https:\/\/doi.org\/10.1016\/j.bbadis.2012.09.006","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"970_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jchromb.2018.05.011","volume":"1090","author":"JJM Rood","year":"2018","unstructured":"Rood JJM, Dormans PJA, van Haren MJ, Schellens JHM, Beijnen JH, Sparidans RW (2018) Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. J Chromatogr B 1090:14\u201321. https:\/\/doi.org\/10.1016\/j.jchromb.2018.05.011","journal-title":"J Chromatogr B"},{"key":"970_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10928-015-9432-2","volume":"42","author":"WS Denney","year":"2015","unstructured":"Denney WS, Duvvuri S, Buckeridge C (2015) Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn 42:11\u2013107. https:\/\/doi.org\/10.1007\/s10928-015-9432-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"970_CR23","unstructured":"R Core Team. (2016) R: A Language and Environment for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 3 Dec 2016"},{"key":"970_CR24","unstructured":"RStudio Team (2016) RStudio: Integrated Development Environment for R. http:\/\/www.rstudio.com\/. Accessed 3 Dec 2016"},{"key":"970_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1023\/A:1027310328310","volume":"22","author":"R Dringen","year":"1997","unstructured":"Dringen R, Kranich O, Hamprecht B (1997) The \u0263-glutamyl transpeptidase inhibitor activicin preserves glutathione released by astroglial cells in culture. Neurochem Res 22:727\u2013733","journal-title":"Neurochem Res"},{"key":"970_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/12.suppl_D.1","volume":"12","author":"FM Kahan","year":"1983","unstructured":"Kahan FM, Kropp H, Sundelof JG, Birnbaum J (1983) Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother 12:1\u201335. https:\/\/doi.org\/10.1093\/jac\/12.suppl_D.1","journal-title":"J Antimicrob Chemother"},{"key":"970_CR27","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Czerwinski M, Slattery JT (1996) Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 56:3678\u20133681","journal-title":"Cancer Res"},{"key":"970_CR28","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1021\/acs.jmedchem.5b01018","volume":"58","author":"VJ Cee","year":"2015","unstructured":"Cee VJ, Volak LP, Chen Y, Bartberger MD, Tegley C, Arvedson T, McCarter J, Tasker AS, Fotsch C (2015) Systematic study of the glutathione (GSH) reactivity of N-arylacrylamides: 1. Effects of aryl substitution. J Med Chem 58:9171\u20139178. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01018","journal-title":"J Med Chem"},{"key":"970_CR29","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s11095-014-1609-7","volume":"23","author":"A Kort","year":"2015","unstructured":"Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2015) Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1). Pharm Res 23:2205\u20132216. https:\/\/doi.org\/10.1007\/s11095-014-1609-7","journal-title":"Pharm Res"},{"key":"970_CR30","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1021\/acs.molpharmaceut.8b00702","volume":"15","author":"S van Hoppe","year":"2018","unstructured":"van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH (2018) P -glycoprotein (MDR1\/ABCB1) restricts brain penetration of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib, while cytochrome P450-3A (CYP3A) limits its oral bioavailability. Mol Pharm 15:5124\u20135134. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00702","journal-title":"Mol Pharm"},{"key":"970_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jpba.2015.10.033","volume":"118","author":"JJM Rood","year":"2016","unstructured":"Rood JJM, van Hoppe S, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW (2016) Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. J Pharm Biomed Anal 118:123\u2013131. https:\/\/doi.org\/10.1016\/j.jpba.2015.10.033","journal-title":"J Pharm Biomed Anal"},{"key":"970_CR32","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.fct.2011.05.017","volume":"49","author":"R Katayama","year":"2011","unstructured":"Katayama R, Nagata S, Iida H, Yamagishi N, Yamashita T, Furuhama K (2011) Possible role of cysteine-S-conjugate \u03b2-lyase in species differences in cisplatin nephrotoxicity. Food Chem Toxicol 49:2053\u20132059. https:\/\/doi.org\/10.1016\/j.fct.2011.05.017","journal-title":"Food Chem Toxicol"},{"key":"970_CR33","first-page":"271","volume":"47","author":"JNM Commandeur","year":"1995","unstructured":"Commandeur JNM, Stijntjes GJ, Vermeulen NPE (1995) Enzymes formation and transport and systems involved in the of glutathione. Pharmacol Rev 47:271\u2013330","journal-title":"Pharmacol Rev"},{"key":"970_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00726-010-0552-0","volume":"41","author":"AJL Cooper","year":"2011","unstructured":"Cooper AJL, Krasnikov BF, Niatsetskaya ZV, Pinto JT, Callery PS, Villar MT, Artigues A, Bruschi SA (2011) Cysteine S-conjugate \u03b2-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino Acids 41:7\u201327. https:\/\/doi.org\/10.1007\/s00726-010-0552-0","journal-title":"Amino Acids"},{"key":"970_CR35","doi-asserted-by":"crossref","unstructured":"Cristofori P, Sauer AV, Trevisan A (2015) Three common pathways of nephrotoxicity induced by halogenated alkenes. Cell Biol Toxicol:31","DOI":"10.1007\/s10565-015-9293-x"},{"key":"970_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/B978-0-12-420117-0.00003-7","volume":"122","author":"MH Hanigan","year":"2014","unstructured":"Hanigan MH (2014) Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res 122:103\u2013141. https:\/\/doi.org\/10.1016\/B978-0-12-420117-0.00003-7","journal-title":"Adv Cancer Res"},{"key":"970_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1208\/s12248-016-9871-8","volume":"18","author":"TTG Nieskens","year":"2016","unstructured":"Nieskens TTG, Peters JGP, Schreurs MJ, Smits N, Woestenenk R, Jansen K, van der Made TK, R\u00f6ring M, Hilgendorf C, Wilmer MJ, Masereeuw R (2016) A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J 18:465\u2013475. https:\/\/doi.org\/10.1208\/s12248-016-9871-8","journal-title":"AAPS J"},{"key":"970_CR38","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369\u20137375. https:\/\/doi.org\/10.1038\/sj.onc.1206940","journal-title":"Oncogene"},{"key":"970_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/cbf.1149","volume":"22","author":"GK Balendiran","year":"2004","unstructured":"Balendiran GK, Dabur R, Fraser D (2004) The role of glutathione in cancer. Cell Biochem Funct 22:343\u2013352. https:\/\/doi.org\/10.1002\/cbf.1149","journal-title":"Cell Biochem Funct"},{"key":"970_CR40","doi-asserted-by":"publisher","unstructured":"Berhane K, Widersten M, Engstr\u00f6m a., et al (1994) Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc Natl Acad Sci U S A 91:1480\u20131484. https:\/\/doi.org\/10.1073\/pnas.91.4.1480","DOI":"10.1073\/pnas.91.4.1480"},{"key":"970_CR41","first-page":"3562","volume":"50","author":"JC Schisselbauer","year":"1990","unstructured":"Schisselbauer JC, LaCreta FP, Tew KD et al (1990) Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res 50:3562\u20133568","journal-title":"Cancer Res"},{"key":"970_CR42","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1158\/1078-0432.CCR-03-0554","volume":"10","author":"A Bennaceur-Griscelli","year":"2004","unstructured":"Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefr\u00e8re F, Turhan A, Brousse N, Hermine O, Ribrag V (2004) High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10:3029\u20133034. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0554","journal-title":"Clin Cancer Res"},{"key":"970_CR43","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1128\/AAC.02931-15","volume":"60","author":"VJC Lempers","year":"2016","unstructured":"Lempers VJC, van den Heuvel JJMW, Russel FGM, Aarnoutse RE, Burger DM, Br\u00fcggemann RJ, Koenderink JB (2016) Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother 60:3372\u20133379. https:\/\/doi.org\/10.1128\/AAC.02931-15","journal-title":"Antimicrob Agents Chemother"},{"key":"970_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bcp.12787","volume":"81","author":"R De Vries","year":"2016","unstructured":"De Vries R, Smit JW, Hellemans P et al (2016) Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. Br J Clin Pharmacol 81:235\u2013245. https:\/\/doi.org\/10.1111\/bcp.12787","journal-title":"Br J Clin Pharmacol"},{"key":"970_CR45","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1124\/dmd.108.022491","volume":"36","author":"CE Grant","year":"2008","unstructured":"Grant CE, Gao M, DeGorter MK et al (2008) Structural determinants of substrate specificity differences between human multidrug resistance protein MRP1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos 36:2571\u20132581. https:\/\/doi.org\/10.1124\/dmd.108.022491","journal-title":"Drug Metab Dispos"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00970-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:52:56Z","timestamp":1678492376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00970-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00970-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Mice were housed and handled according to institutional guidelines of the Netherlands Cancer Institute complying with Dutch legislation.Patient samples (anonymized) were taken and analyzed for therapeutic drug monitoring as part of routine clinical care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient samples (anonymized) were taken and analyzed for therapeutic drug monitoring as part of routine clinical care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patient samples (anonymized) were taken and analyzed for therapeutic drug monitoring as part of routine clinical care.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}